Kayce Blumenstock^1,2, Vandana Zaman^2,3, Camille Green³, Narendra L. Banik^1,2,3, Azizul Haque^1,2,3,*

BIOCELL, Vol.49, No.10, pp. 1859-1871, 2025, DOI:10.32604/biocell.2025.068773 - 22 October 2025

Abstract Fc Receptor-Like 1 (FCRL1), a member of the FCRL family, contains two immunoreceptor tyrosine-based activation motifs (ITAMs) in its cytoplasmic domain and plays a critical role in B-cell biology. Its expression begins in pre-B-cells, dynamically shifts during B-cell development, and contributes to the regulation of human B-cell activation. Notably, FCRL1 is overexpressed in subsets of naive and memory B-cells, as well as in malignant B-cells, including those in diffuse large B-cell lymphoma (DLBCL), an aggressive and often treatment-resistant hematological malignancy. Among FCRL family members, FCRL1 stands out as a promising immunotherapeutic target due to its More >

Weiwei Chen¹, Xiaodie Zhou², Huiyu Li¹, Yuchen Yang¹, Lu Lu¹, Chunyan Zhu¹, Rong Fang¹, Xiaoyuan Chu¹, Shuping Zhou^3,*, Qian Sun^1,*

Oncology Research, Vol.33, No.8, pp. 2123-2139, 2025, DOI:10.32604/or.2025.063484 - 18 July 2025

Abstract Background: Primary bone marrow diffuse large B-cell lymphoma (PBM-DLBCL) represents an uncommon yet clinically aggressive hematologic malignancy. Despite its significant clinical impact, this entity lacks standardized diagnostic criteria in current WHO classifications. Methods: We performed a retrospective analysis of 55 PBM-DLBCL cases from our institutional database and published literature (2001–2022) to characterize disease features and identify prognostic factors, with particular focus on assessing how different treatment regimens influence therapeutic efficacy and long-term outcomes. Results: The data suggested a potential link between international prognostic index (IPI) scores and poorer survival, albeit without conclusive statistical evidence (p = More >

WEN YANG, BIN TANG, DAN XU, WENXIU YANG^*

Oncology Research, Vol.33, No.1, pp. 199-212, 2025, DOI:10.32604/or.2024.050036 - 20 December 2024

Abstract Background: The prognostic significance of the chemokine receptor CCR7 in diffuse large B-cell lymphoma (DLBCL) has been reported previously. However, the detailed mechanisms of CCR7 in DLBCL, particularly regarding its interaction with lenalidomide treatment, are not fully understood. Methods: Our study utilized bioinformatics approaches to identify hub genes in SU-DHL-2 cell lines treated with lenalidomide compared to control groups. Immunohistochemical data and clinical information from 122 patients with DLBCL were analyzed to assess the correlation of CCR7 and p-ERK1/2 expression with the prognosis of DLBCL. Furthermore, in vitro and in vivo experiments were conducted to clarify the… More > Graphic Abstract

Qiuyun Luo^*†1, Wentao Pan^*†‡1, Suna Zhou^*†1, Guangfeng Wang^‡, Hanjie Yi^*§, Lin Zhang^*¶, Xianglei Yan^*†, Luping Yuan^*†, Zhenyi Liu^#, Jing Wang^**, Haibo Chen^#, MiaoZhen Qiu^*††, DaJun Yang^*†‡, Jian Sun^*‡‡

Oncology Research, Vol.28, No.4, pp. 331-344, 2020, DOI:10.3727/096504020X15825405463920

Abstract Despite therapeutic advances, the effective treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains a major clinical challenge. Evasion of apoptosis through upregulating antiapoptotic B-cell lymphoma-2 (BCL-2) family members and p53 inactivation, and abnormal activation of B-cell receptor signaling pathway are two important pathogenic factors for DLBCL. In this study, our aim is to explore a rational combination of BCL-2 inhibitor plus Bruton’s tyrosine kinase (BTK) blockade or p53 activation for treating DLBCL with the above characteristics. We demonstrated that a novel BCL-2 selective inhibitor APG-2575 effectively suppressed DLBCL with BCL-2 high expression… More >

Takashi Saito^*†, Atsuo Okamura^‡, Junichiro Inoue^†, Daisuke Makiura^†, Hisayo Doi^§, Kimikazu Yakushijin^¶, Hiroshi Matsuoka^¶, Yoshitada Sakai^†#, Rei Ono^*

Oncology Research, Vol.27, No.4, pp. 469-474, 2019, DOI:10.3727/096504018X15267574931782

Abstract Chemotherapy-induced peripheral neuropathy (CIPN) frequently occurs in lymphoma patients receiving R-CHOP, a drug combination therapy. Although severe CIPN may lead to reduction and/or discontinuation of the medication, predictive factors of CIPN have not been investigated sufficiently to date. We performed a retrospective exploratory research to determine associations between prevalence of severe CIPN and sociodemographic data, health characteristics, and medical conditions such as anemia at initial diagnosis. Forty patients (indolent lymphoma, n=9; diffuse large B-cell lymphoma; n=31) received R-CHOP therapy from September 2009 to July 2014. The median age of patients was 58 years (range=27–76 years). Statistical More >